10-Q · May 7, 2026
CytomX Therapeutics reported decreased revenue of $10.3 million in Q1 2026, down 80% from $50.9 million in Q1 2025. The company continues to incur significant losses, with a diluted EPS of -$0.46, compared to $0.27 in…
CTMX earnings analysis
10-Q · Filed November 5, 2026 · Our reading of the company's report
The latest report
The filing presents a highly cash-funded but loss-making clinical-stage biotechnology company with no product-sales revenue and an accumulated deficit of $770.9 million as of September 30, 2026. Liquidity improved…
Read full summary
The filing presents a highly cash-funded but loss-making clinical-stage biotechnology company with no product-sales revenue and an accumulated deficit of $770.9 million as of September 30, 2026. Liquidity improved substantially to $348.0 million, and management expects funding to support operations into the second half of 2028, but additional capital will still be required. Varseta-M received fast track designation, yet the pipeline remains early stage and faces substantial clinical, manufacturing, collaboration and financing risks.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Liquidity increased materially
Cash, cash equivalents and short-term investments were $348.0 million as of September 30, 2026, compared with $137.1 million at December 31, 2025.
-
Cash runway extends into 2028
Management states that the $348.0 million capital balance is sufficient to fund planned operations into the second half of 2028.
-
Regeneron collaboration generated cash
The company received a $37.0 million upfront payment from Regeneron in July 2026 related to an expanded collaboration agreement.
-
Equity financing strengthened balance sheet
The company raised approximately $234.2 million of net proceeds through an equity offering in March 2026.
-
Varseta-M received fast track status
The FDA granted Varseta-M fast track designation on August 27, 2026 for relapsed/refractory metastatic colorectal cancer.
-
No reported control deficiencies
Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2026, and reported no material change in internal control during the quarter.
What to watch
-
Persistent losses and no product revenue
The company has never generated revenue from product sales, had an accumulated deficit of $770.9 million as of September 30, 2026 versus $711.9 million at December 31, 2025, and expects significant losses to continue.
-
Future capital raises remain necessary
Management states that additional funding will be required despite $348.0 million of cash, cash equivalents and short-term investments, creating dilution, financing-market and execution risk if capital is unavailable on acceptable terms.
-
Partner and milestone revenue risk
The filing reports that Astellas terminated a collaboration effective in the second quarter of 2026, while the company also states that it will not receive milestone or other payments after the March 2025 termination of the CX-904 program.
-
Early-stage clinical safety risk
Varseta-M and CX-801 remain in Phase 1 clinical trials, and the filing cites a single Grade 5 treatment-related acute kidney injury reported in August 2025, underscoring clinical safety and development risk.
-
Foreign manufacturing and BIOSECURE risk
The company relies on foreign third-party manufacturing, including a contract manufacturer in China, and states that the BIOSECURE Act enacted in 2025 could restrict access to certain biotechnology suppliers or services.
-
Concentrated ownership
The company states that approximately 49% of outstanding common stock was beneficially owned by executive officers, directors and 5% stockholders as of September 30, 2026, creating concentrated voting control.
Management's outlook
No numeric revenue or EPS guidance is provided. Management states that existing capital resources of $348.0 million are expected to fund planned operations into the second half of 2028, while noting that additional funding will be required.
Earlier filings 4
10-K · March 16, 2026
CytomX Therapeutics, a clinical-stage biopharmaceutical company, reported a significant decline in revenue and continued losses as it focuses on developing its PROBODY platform for oncology. The company experienced a…
10-Q · November 6, 2025
CytomX Therapeutics reported a significant decline in revenue and increased losses for Q3 2025 compared to both the prior quarter and the previous year. Revenue fell to $5.963 million, a decrease of 83% from $33.432…
10-Q · August 7, 2025
CytomX Therapeutics reported a decline in Q2 2025 revenue to $18.7 million, a decrease from $25.1 million in Q2 2024, attributed mainly to reduced collaboration revenue. Operating expenses also dropped significantly,…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
See every CTMX trade live.
The free pages stop at the last full session. Trader shows every trade as it prints.
Start tracking No card needed.